CALP1 TFA是一种由八个残基组成的互补肽，可结合钙调蛋白的钙结合位点（EF手结构域）。
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
CALP1 TFA is an eight-residue complementary peptide that binds to the calcium-binding sites (the EF hand) of calmodulin [1]. CALP1 TFA interacts with the two carboxyl-terminal Ca2+-binding sites of calmodulin as well as the EF hands of troponin C, which results in a conformational change and activates phosphodiesterase in the absence of Ca2+[2]. CALP1 TFA has been widely used in allergic asthma models to mitigate the development of airway hyperresponsiveness [3].
In vitro, CALP1 TFA treatment (20µM) for 2 hours can increase the expression of the VPAC1 protein on the surface of monocytes infected by Salmonella[4]. 100µM of CALP1 TFA pretreatment for 15 minutes can reduce the excessive cytoplasmic Ca2+ signal and necrosis in mouse pancreatic acinar cells (PACs) induced by BH3I-2′[5]. Treatment with 100µM CALP1 TFA for 60 minutes can inhibit the adhesion of murine bone marrow-derived mast cells (BMMCs) to fibronectin induced by FcεRI[6]. Treatment with 10µM CALP1 TFA for 48 hours significantly inhibited the expression of TGF-β2 and IL-10 in C2C12 cells and promoted the upregulation of p-CaMKII, p-CaMKIV, and NFATc2 levels after IFN-γ stimulation[7].
In vivo, thirty minutes before ovalbumin challenge, a single dose of CALP1 TFA (1mg/ml; 0.1ml) was injected intratracheally, significantly reducing the infiltration of alveolar macrophages in the lungs of guinea pigs stimulated by ovalbumin and inhibiting the generation of free radicals[8].
References:
[1] Folkerts G, Nijkamp F P. Airway nitrergic pathways: is there therapeutic potential in asthma and COPD?[J]. Current Opinion in Pharmacology, 2004, 4(3): 202-206.
[2] Villain M, Jackson P L, Manion M K, et al. De novo design of peptides targeted to the EF hands of calmodulin[J]. Journal of Biological Chemistry, 2000, 275(4): 2676-2685.
[3] Ten Broeke R, Leusink-Muis T, Hilberdink R, et al. Specific modulation of calmodulin activity induces a dramatic production of superoxide by alveolar macrophages[J]. Laboratory investigation, 2004, 84(1): 29-40.
[4] Askar B, Higgins J, Barrow P, et al. Immune evasion by Salmonella: exploiting the VPAC 1/VIP axis in human monocytes[J]. Immunology, 2019, 158(3): 230-239.
[5] Ferdek P E, Jakubowska M A, Nicolaou P, et al. BH3 mimetic-elicited Ca2+ signals in pancreatic acinar cells are dependent on Bax and can be reduced by Ca2+-like peptides[J]. Cell Death & Disease, 2017, 8(3): e2640-e2640.
[6] Houtman R, Ten Broeke R, Blalock J E, et al. Attenuation of very late antigen-5-mediated adhesion of bone marrow-derived mast cells to fibronectin by peptides with inverted hydropathy to EF-hands[J]. The Journal of Immunology, 2001, 166(2): 861-867.
[7] Hu J, Shi D, Ding M, et al. Calmodulin‐dependent signalling pathways are activated and mediate the acute inflammatory response of injured skeletal muscle[J]. The Journal of physiology, 2019, 597(21): 5161-5177.
[8] Ten Broeke R, Brandhorst M C, Leusink-Muis T, et al. Ca2+ sensors modulate asthmatic symptoms in an allergic model for asthma[J]. European journal of pharmacology, 2003, 476(1-2): 151-157.
CALP1 TFA是一种由八个残基组成的互补肽，可结合钙调蛋白的钙结合位点（EF手结构域）[1]。CALP1 TFA与钙调蛋白的两个羧基末端Ca2+结合位点以及肌钙蛋白C的EF手形结构相互作用，导致构象变化，并在无Ca2+条件下激活磷酸二酯酶[2]。CALP1 TFA已被广泛用于过敏性哮喘模型，以减轻气道高反应性的发展[3]。
在体外，20µM的CALP1 TFA处理2小时可增加感染沙门氏菌的单核细胞表面VPAC1蛋白的表达[4]。100µM的CALP1 TFA预处理15分钟可减少BH3I-2′诱导的小鼠胰腺腺泡细胞(PACs)中过度的细胞质Ca2+信号和坏死[5]。100µM的CALP1 TFA处理60分钟可抑制FcεRI诱导的小鼠骨髓来源肥大细胞(BMMCs)与纤连蛋白的粘附[6]。10µM的CALP1 TFA处理C2C12细胞48小时，显著抑制了TGF-β2和IL-10的表达，并在IFN-γ刺激后促进 p-CaMKII、p-CaMKIV和NFATc2水平的上调[7]。
在体内，在卵清蛋白激发前30分钟，单次气管内注射（0.1ml）1mg/ml的CALP1 TFA，可显著减少卵清蛋白刺激的豚鼠肺部肺泡巨噬细胞的浸润，并抑制自由基的产生[8]。
| Cell experiment [1]: | |
Cell lines | Bone marrow-derived mast cells (BMMCs) |
Preparation Method | BMMCs from BALB/c mice were cultured in RPMI 1640 medium supplemented with 4mM L-glutamine, 0.05µM 2-ME, 1mM sodium pyruvate, 100U/ml penicillin, 100mg/ml streptomycin, and 0.1mM nonessential amino acids in 5% CO2 at 37°C. Cells were placed in a 96 well-plate at a concentration of 5×105 cells per well and were treated with different concentrations of CALP1 TFA (0, 1, 10, 100µM) and 30ng/ml DNP-HAS (FcεRI clustering) for 30min, and then the Effect of CALP1 TFA on the degranulation of BMMCs was analyzed. |
Reaction Conditions | 0, 1, 10, 100µM; 30min |
Applications | CALP1 TFA treatment significantly reduced FcεRI-induced degranulation in BMMCs. |
| Animal experiment [2]: | |
Animal models | Guinea pigs |
Preparation Method | Specified-pathogen-free guinea pigs (300-400g) were housed in a specialized animal care facility, in a room with constant temperature (25°C), humidity control, and a 12/12h light/dark cycle with free access to food and water. Thirty minutes before ovalbumin challenge, guinea pigs received the control solution (0.1ml; positive control), CALP1 TFA (1mg/ml; 0.1ml), or CALP2 (3mg/ml; 0.1ml) intratracheally. Therefore, the guinea pigs were anaesthetized with halothane and placed in a supine position on a table. The jaws were kept apart by two elastic bands, and a needle with a bulbous tip was inserted just behind the glottis. Thereafter, 0.1ml of the solution was gently injected into the trachea, the bands were removed, and the chest was gently massaged. Broncho-alveolar lavage cells were obtained from pigs for analysis. |
Dosage form | 1mg/ml (1ml) for once; intratracheal injection |
Applications | CALP1 TFA treatment significantly reduced the influx of alveolar macrophages into the lungs of ovalbumin-challenged guinea pigs 6h after challenge. |
References: | |
| Cas No. | SDF | Download SDF | |
| 分子式 | C42H76F3N9O12 | 分子量 | 956.1 |
| 溶解度 | Water : 16.67 mg/mL (17.44 mM; Need ultrasonic) | 储存条件 | -20°C, away from moisture |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.0459 mL | 5.2296 mL | 10.4592 mL |
| 5 mM | 209.2 μL | 1.0459 mL | 2.0918 mL |
| 10 mM | 104.6 μL | 523 μL | 1.0459 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet